Pharma & Healthcare
Global Opioid Narcotics Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 21, 25
- ID: 556935
- Pages: 151
- Figures: 163
- Views: 11
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Opioid Narcotics market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Yichang Renfu Pharmaceutical Co., Ltd.
Jiangsu Enhua Pharmaceutical Co., Ltd.
Henan Lingrui Pharmaceutical Co., Ltd.
Sinopharm Group Industrial Co., Ltd. Langfang Branch
Changzhou Siyao Pharmaceutical Co., Ltd.
Pfizer
Fresenius Kabi
Daiichi Sankyo
Abbott
GSK
Reig Jofre
AcelRx Pharmaceuticals, Inc
Segment by Type
Fentanyl
Remifentanil
Sufentanil
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Opioid Narcotics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Opioid Narcotics market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Yichang Renfu Pharmaceutical Co., Ltd.
Jiangsu Enhua Pharmaceutical Co., Ltd.
Henan Lingrui Pharmaceutical Co., Ltd.
Sinopharm Group Industrial Co., Ltd. Langfang Branch
Changzhou Siyao Pharmaceutical Co., Ltd.
Pfizer
Fresenius Kabi
Daiichi Sankyo
Abbott
GSK
Reig Jofre
AcelRx Pharmaceuticals, Inc
Segment by Type
Fentanyl
Remifentanil
Sufentanil
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Opioid Narcotics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Opioid Narcotics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Opioid Narcotics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Fentanyl
1.2.3 Remifentanil
1.2.4 Sufentanil
1.3 Market Segmentation by Application
1.3.1 Global Opioid Narcotics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Opioid Narcotics Revenue Estimates and Forecasts 2020-2031
2.2 Global Opioid Narcotics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Opioid Narcotics Sales Estimates and Forecasts 2020-2031
2.4 Global Opioid Narcotics Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Opioid Narcotics Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Opioid Narcotics Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Fentanyl Market Size by Manufacturers
3.5.2 Remifentanil Market Size by Manufacturers
3.5.3 Sufentanil Market Size by Manufacturers
3.6 Global Opioid Narcotics Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Opioid Narcotics Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Opioid Narcotics Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Opioid Narcotics Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Opioid Narcotics Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Opioid Narcotics Sales and Revenue by Type (2020-2031)
6.4 North America Opioid Narcotics Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Opioid Narcotics Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Opioid Narcotics Sales and Revenue by Type (2020-2031)
7.4 Europe Opioid Narcotics Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Opioid Narcotics Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Opioid Narcotics Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Opioid Narcotics Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Opioid Narcotics Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Opioid Narcotics Sales and Revenue by Type (2020-2031)
9.4 Central and South America Opioid Narcotics Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Opioid Narcotics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Opioid Narcotics Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Opioid Narcotics Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Opioid Narcotics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Yichang Renfu Pharmaceutical Co., Ltd.
11.1.1 Yichang Renfu Pharmaceutical Co., Ltd. Corporation Information
11.1.2 Yichang Renfu Pharmaceutical Co., Ltd. Business Overview
11.1.3 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.1.4 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.1.6 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.1.7 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.1.8 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.1.9 Yichang Renfu Pharmaceutical Co., Ltd. Recent Developments
11.2 Jiangsu Enhua Pharmaceutical Co., Ltd.
11.2.1 Jiangsu Enhua Pharmaceutical Co., Ltd. Corporation Information
11.2.2 Jiangsu Enhua Pharmaceutical Co., Ltd. Business Overview
11.2.3 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.2.4 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.2.6 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.2.7 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.2.8 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.2.9 Jiangsu Enhua Pharmaceutical Co., Ltd. Recent Developments
11.3 Henan Lingrui Pharmaceutical Co., Ltd.
11.3.1 Henan Lingrui Pharmaceutical Co., Ltd. Corporation Information
11.3.2 Henan Lingrui Pharmaceutical Co., Ltd. Business Overview
11.3.3 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.3.4 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.3.6 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.3.7 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.3.8 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.3.9 Henan Lingrui Pharmaceutical Co., Ltd. Recent Developments
11.4 Sinopharm Group Industrial Co., Ltd. Langfang Branch
11.4.1 Sinopharm Group Industrial Co., Ltd. Langfang Branch Corporation Information
11.4.2 Sinopharm Group Industrial Co., Ltd. Langfang Branch Business Overview
11.4.3 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Product Models, Descriptions and Specifications
11.4.4 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales by Product in 2024
11.4.6 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales by Application in 2024
11.4.7 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales by Geographic Area in 2024
11.4.8 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics SWOT Analysis
11.4.9 Sinopharm Group Industrial Co., Ltd. Langfang Branch Recent Developments
11.5 Changzhou Siyao Pharmaceutical Co., Ltd.
11.5.1 Changzhou Siyao Pharmaceutical Co., Ltd. Corporation Information
11.5.2 Changzhou Siyao Pharmaceutical Co., Ltd. Business Overview
11.5.3 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.5.4 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.5.6 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.5.7 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.5.8 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.5.9 Changzhou Siyao Pharmaceutical Co., Ltd. Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Opioid Narcotics Product Models, Descriptions and Specifications
11.6.4 Pfizer Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Pfizer Recent Developments
11.7 Fresenius Kabi
11.7.1 Fresenius Kabi Corporation Information
11.7.2 Fresenius Kabi Business Overview
11.7.3 Fresenius Kabi Opioid Narcotics Product Models, Descriptions and Specifications
11.7.4 Fresenius Kabi Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Fresenius Kabi Recent Developments
11.8 Daiichi Sankyo
11.8.1 Daiichi Sankyo Corporation Information
11.8.2 Daiichi Sankyo Business Overview
11.8.3 Daiichi Sankyo Opioid Narcotics Product Models, Descriptions and Specifications
11.8.4 Daiichi Sankyo Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Daiichi Sankyo Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview
11.9.3 Abbott Opioid Narcotics Product Models, Descriptions and Specifications
11.9.4 Abbott Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Abbott Recent Developments
11.10 GSK
11.10.1 GSK Corporation Information
11.10.2 GSK Business Overview
11.10.3 GSK Opioid Narcotics Product Models, Descriptions and Specifications
11.10.4 GSK Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 GSK Recent Developments
11.11 Reig Jofre
11.11.1 Reig Jofre Corporation Information
11.11.2 Reig Jofre Business Overview
11.11.3 Reig Jofre Opioid Narcotics Product Models, Descriptions and Specifications
11.11.4 Reig Jofre Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Reig Jofre Recent Developments
11.12 AcelRx Pharmaceuticals, Inc
11.12.1 AcelRx Pharmaceuticals, Inc Corporation Information
11.12.2 AcelRx Pharmaceuticals, Inc Business Overview
11.12.3 AcelRx Pharmaceuticals, Inc Opioid Narcotics Product Models, Descriptions and Specifications
11.12.4 AcelRx Pharmaceuticals, Inc Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 AcelRx Pharmaceuticals, Inc Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Opioid Narcotics Industry Chain
12.2 Opioid Narcotics Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Opioid Narcotics Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Opioid Narcotics Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Opioid Narcotics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Opioid Narcotics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Opioid Narcotics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Opioid Narcotics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Fentanyl
1.2.3 Remifentanil
1.2.4 Sufentanil
1.3 Market Segmentation by Application
1.3.1 Global Opioid Narcotics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Opioid Narcotics Revenue Estimates and Forecasts 2020-2031
2.2 Global Opioid Narcotics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Opioid Narcotics Sales Estimates and Forecasts 2020-2031
2.4 Global Opioid Narcotics Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Opioid Narcotics Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Opioid Narcotics Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Fentanyl Market Size by Manufacturers
3.5.2 Remifentanil Market Size by Manufacturers
3.5.3 Sufentanil Market Size by Manufacturers
3.6 Global Opioid Narcotics Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Opioid Narcotics Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Opioid Narcotics Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Opioid Narcotics Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Opioid Narcotics Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Opioid Narcotics Sales and Revenue by Type (2020-2031)
6.4 North America Opioid Narcotics Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Opioid Narcotics Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Opioid Narcotics Sales and Revenue by Type (2020-2031)
7.4 Europe Opioid Narcotics Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Opioid Narcotics Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Opioid Narcotics Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Opioid Narcotics Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Opioid Narcotics Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Opioid Narcotics Sales and Revenue by Type (2020-2031)
9.4 Central and South America Opioid Narcotics Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Opioid Narcotics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Opioid Narcotics Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Opioid Narcotics Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Opioid Narcotics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Yichang Renfu Pharmaceutical Co., Ltd.
11.1.1 Yichang Renfu Pharmaceutical Co., Ltd. Corporation Information
11.1.2 Yichang Renfu Pharmaceutical Co., Ltd. Business Overview
11.1.3 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.1.4 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.1.6 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.1.7 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.1.8 Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.1.9 Yichang Renfu Pharmaceutical Co., Ltd. Recent Developments
11.2 Jiangsu Enhua Pharmaceutical Co., Ltd.
11.2.1 Jiangsu Enhua Pharmaceutical Co., Ltd. Corporation Information
11.2.2 Jiangsu Enhua Pharmaceutical Co., Ltd. Business Overview
11.2.3 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.2.4 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.2.6 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.2.7 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.2.8 Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.2.9 Jiangsu Enhua Pharmaceutical Co., Ltd. Recent Developments
11.3 Henan Lingrui Pharmaceutical Co., Ltd.
11.3.1 Henan Lingrui Pharmaceutical Co., Ltd. Corporation Information
11.3.2 Henan Lingrui Pharmaceutical Co., Ltd. Business Overview
11.3.3 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.3.4 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.3.6 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.3.7 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.3.8 Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.3.9 Henan Lingrui Pharmaceutical Co., Ltd. Recent Developments
11.4 Sinopharm Group Industrial Co., Ltd. Langfang Branch
11.4.1 Sinopharm Group Industrial Co., Ltd. Langfang Branch Corporation Information
11.4.2 Sinopharm Group Industrial Co., Ltd. Langfang Branch Business Overview
11.4.3 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Product Models, Descriptions and Specifications
11.4.4 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales by Product in 2024
11.4.6 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales by Application in 2024
11.4.7 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics Sales by Geographic Area in 2024
11.4.8 Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics SWOT Analysis
11.4.9 Sinopharm Group Industrial Co., Ltd. Langfang Branch Recent Developments
11.5 Changzhou Siyao Pharmaceutical Co., Ltd.
11.5.1 Changzhou Siyao Pharmaceutical Co., Ltd. Corporation Information
11.5.2 Changzhou Siyao Pharmaceutical Co., Ltd. Business Overview
11.5.3 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Product Models, Descriptions and Specifications
11.5.4 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Product in 2024
11.5.6 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Application in 2024
11.5.7 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics Sales by Geographic Area in 2024
11.5.8 Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
11.5.9 Changzhou Siyao Pharmaceutical Co., Ltd. Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Opioid Narcotics Product Models, Descriptions and Specifications
11.6.4 Pfizer Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Pfizer Recent Developments
11.7 Fresenius Kabi
11.7.1 Fresenius Kabi Corporation Information
11.7.2 Fresenius Kabi Business Overview
11.7.3 Fresenius Kabi Opioid Narcotics Product Models, Descriptions and Specifications
11.7.4 Fresenius Kabi Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Fresenius Kabi Recent Developments
11.8 Daiichi Sankyo
11.8.1 Daiichi Sankyo Corporation Information
11.8.2 Daiichi Sankyo Business Overview
11.8.3 Daiichi Sankyo Opioid Narcotics Product Models, Descriptions and Specifications
11.8.4 Daiichi Sankyo Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Daiichi Sankyo Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview
11.9.3 Abbott Opioid Narcotics Product Models, Descriptions and Specifications
11.9.4 Abbott Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Abbott Recent Developments
11.10 GSK
11.10.1 GSK Corporation Information
11.10.2 GSK Business Overview
11.10.3 GSK Opioid Narcotics Product Models, Descriptions and Specifications
11.10.4 GSK Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 GSK Recent Developments
11.11 Reig Jofre
11.11.1 Reig Jofre Corporation Information
11.11.2 Reig Jofre Business Overview
11.11.3 Reig Jofre Opioid Narcotics Product Models, Descriptions and Specifications
11.11.4 Reig Jofre Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Reig Jofre Recent Developments
11.12 AcelRx Pharmaceuticals, Inc
11.12.1 AcelRx Pharmaceuticals, Inc Corporation Information
11.12.2 AcelRx Pharmaceuticals, Inc Business Overview
11.12.3 AcelRx Pharmaceuticals, Inc Opioid Narcotics Product Models, Descriptions and Specifications
11.12.4 AcelRx Pharmaceuticals, Inc Opioid Narcotics Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 AcelRx Pharmaceuticals, Inc Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Opioid Narcotics Industry Chain
12.2 Opioid Narcotics Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Opioid Narcotics Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Opioid Narcotics Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Opioid Narcotics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Opioid Narcotics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Opioid Narcotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Opioid Narcotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Opioid Narcotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Opioid Narcotics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Opioid Narcotics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Opioid Narcotics Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Opioid Narcotics Sales by Region (2020-2025) & (K Units)
Table 8. Global Opioid Narcotics Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Opioid Narcotics Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Opioid Narcotics Sales Share by Manufacturers (2020-2025)
Table 12. Global Opioid Narcotics Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Opioid Narcotics Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Opioid Narcotics by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid Narcotics as of 2024)
Table 16. Global Opioid Narcotics Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Opioid Narcotics Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Opioid Narcotics Manufacturing Base and Headquarters
Table 19. Global Opioid Narcotics Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Opioid Narcotics Sales by Type (2020-2025) & (K Units)
Table 23. Global Opioid Narcotics Sales by Type (2026-2031) & (K Units)
Table 24. Global Opioid Narcotics Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Opioid Narcotics Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Opioid Narcotics ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Opioid Narcotics Sales by Application (2020-2025) & (K Units)
Table 29. Global Opioid Narcotics Sales by Application (2026-2031) & (K Units)
Table 30. Opioid Narcotics High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Opioid Narcotics Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Opioid Narcotics Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Opioid Narcotics ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Opioid Narcotics Growth Accelerators and Market Barriers
Table 37. North America Opioid Narcotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Opioid Narcotics Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Opioid Narcotics Growth Accelerators and Market Barriers
Table 40. Europe Opioid Narcotics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Opioid Narcotics Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Opioid Narcotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Opioid Narcotics Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Opioid Narcotics Growth Accelerators and Market Barriers
Table 45. Southeast Asia Opioid Narcotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Opioid Narcotics Investment Opportunities and Key Challenges
Table 47. Central and South America Opioid Narcotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Opioid Narcotics Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Opioid Narcotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Yichang Renfu Pharmaceutical Co., Ltd. Corporation Information
Table 51. Yichang Renfu Pharmaceutical Co., Ltd. Description and Major Businesses
Table 52. Yichang Renfu Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 53. Yichang Renfu Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Yichang Renfu Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 55. Yichang Renfu Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 56. Yichang Renfu Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 57. Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 58. Yichang Renfu Pharmaceutical Co., Ltd. Recent Developments
Table 59. Jiangsu Enhua Pharmaceutical Co., Ltd. Corporation Information
Table 60. Jiangsu Enhua Pharmaceutical Co., Ltd. Description and Major Businesses
Table 61. Jiangsu Enhua Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 62. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 64. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 65. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 66. Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 67. Jiangsu Enhua Pharmaceutical Co., Ltd. Recent Developments
Table 68. Henan Lingrui Pharmaceutical Co., Ltd. Corporation Information
Table 69. Henan Lingrui Pharmaceutical Co., Ltd. Description and Major Businesses
Table 70. Henan Lingrui Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 71. Henan Lingrui Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Henan Lingrui Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 73. Henan Lingrui Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 74. Henan Lingrui Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 75. Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 76. Henan Lingrui Pharmaceutical Co., Ltd. Recent Developments
Table 77. Sinopharm Group Industrial Co., Ltd. Langfang Branch Corporation Information
Table 78. Sinopharm Group Industrial Co., Ltd. Langfang Branch Description and Major Businesses
Table 79. Sinopharm Group Industrial Co., Ltd. Langfang Branch Product Models, Descriptions and Specifications
Table 80. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales Value Proportion by Product in 2024
Table 82. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales Value Proportion by Application in 2024
Table 83. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales Value Proportion by Geographic Area in 2024
Table 84. Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics SWOT Analysis
Table 85. Sinopharm Group Industrial Co., Ltd. Langfang Branch Recent Developments
Table 86. Changzhou Siyao Pharmaceutical Co., Ltd. Corporation Information
Table 87. Changzhou Siyao Pharmaceutical Co., Ltd. Description and Major Businesses
Table 88. Changzhou Siyao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 89. Changzhou Siyao Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Changzhou Siyao Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 91. Changzhou Siyao Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 92. Changzhou Siyao Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 93. Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 94. Changzhou Siyao Pharmaceutical Co., Ltd. Recent Developments
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Major Businesses
Table 97. Pfizer Product Models, Descriptions and Specifications
Table 98. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Pfizer Recent Developments
Table 100. Fresenius Kabi Corporation Information
Table 101. Fresenius Kabi Description and Major Businesses
Table 102. Fresenius Kabi Product Models, Descriptions and Specifications
Table 103. Fresenius Kabi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Fresenius Kabi Recent Developments
Table 105. Daiichi Sankyo Corporation Information
Table 106. Daiichi Sankyo Description and Major Businesses
Table 107. Daiichi Sankyo Product Models, Descriptions and Specifications
Table 108. Daiichi Sankyo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Daiichi Sankyo Recent Developments
Table 110. Abbott Corporation Information
Table 111. Abbott Description and Major Businesses
Table 112. Abbott Product Models, Descriptions and Specifications
Table 113. Abbott Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Abbott Recent Developments
Table 115. GSK Corporation Information
Table 116. GSK Description and Major Businesses
Table 117. GSK Product Models, Descriptions and Specifications
Table 118. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. GSK Recent Developments
Table 120. Reig Jofre Corporation Information
Table 121. Reig Jofre Description and Major Businesses
Table 122. Reig Jofre Product Models, Descriptions and Specifications
Table 123. Reig Jofre Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Reig Jofre Recent Developments
Table 125. AcelRx Pharmaceuticals, Inc Corporation Information
Table 126. AcelRx Pharmaceuticals, Inc Description and Major Businesses
Table 127. AcelRx Pharmaceuticals, Inc Product Models, Descriptions and Specifications
Table 128. AcelRx Pharmaceuticals, Inc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. AcelRx Pharmaceuticals, Inc Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid Narcotics Product Picture
Figure 2. Global Opioid Narcotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Fentanyl Product Picture
Figure 4. Remifentanil Product Picture
Figure 5. Sufentanil Product Picture
Figure 6. Global Opioid Narcotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. Opioid Narcotics Report Years Considered
Figure 11. Global Opioid Narcotics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 13. Global Opioid Narcotics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Opioid Narcotics Revenue Market Share by Region (2020-2031)
Figure 15. Global Opioid Narcotics Sales (2020-2031) & (K Units)
Figure 16. Global Opioid Narcotics Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Opioid Narcotics Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Opioid Narcotics Sales Volume Market Share in 2024
Figure 19. Global Opioid Narcotics Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Fentanyl Revenue Market Share by Manufacturer in 2024
Figure 22. Remifentanil Revenue Market Share by Manufacturer in 2024
Figure 23. Sufentanil Revenue Market Share by Manufacturer in 2024
Figure 24. Global Opioid Narcotics Sales Market Share by Type (2020-2031)
Figure 25. Global Opioid Narcotics Revenue Market Share by Type (2020-2031)
Figure 26. Global Opioid Narcotics Sales Market Share by Application (2020-2031)
Figure 27. Global Opioid Narcotics Revenue Market Share by Application (2020-2031)
Figure 28. North America Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 29. North America Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 31. North America Opioid Narcotics Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Opioid Narcotics Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 41. Europe Opioid Narcotics Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Opioid Narcotics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 46. France Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Opioid Narcotics Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Opioid Narcotics Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 61. India Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Opioid Narcotics Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Opioid Narcotics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Opioid Narcotics Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Opioid Narcotics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 82. Opioid Narcotics Industry Chain Mapping
Figure 83. Regional Opioid Narcotics Manufacturing Base Distribution (%)
Figure 84. Global Opioid Narcotics Production Market Share by Region (2020-2031)
Figure 85. Opioid Narcotics Production Process
Figure 86. Regional Opioid Narcotics Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Table 1. Global Opioid Narcotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Opioid Narcotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Opioid Narcotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Opioid Narcotics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Opioid Narcotics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Opioid Narcotics Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Opioid Narcotics Sales by Region (2020-2025) & (K Units)
Table 8. Global Opioid Narcotics Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Opioid Narcotics Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Opioid Narcotics Sales Share by Manufacturers (2020-2025)
Table 12. Global Opioid Narcotics Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Opioid Narcotics Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Opioid Narcotics by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid Narcotics as of 2024)
Table 16. Global Opioid Narcotics Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Opioid Narcotics Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Opioid Narcotics Manufacturing Base and Headquarters
Table 19. Global Opioid Narcotics Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Opioid Narcotics Sales by Type (2020-2025) & (K Units)
Table 23. Global Opioid Narcotics Sales by Type (2026-2031) & (K Units)
Table 24. Global Opioid Narcotics Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Opioid Narcotics Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Opioid Narcotics ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Opioid Narcotics Sales by Application (2020-2025) & (K Units)
Table 29. Global Opioid Narcotics Sales by Application (2026-2031) & (K Units)
Table 30. Opioid Narcotics High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Opioid Narcotics Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Opioid Narcotics Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Opioid Narcotics ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Opioid Narcotics Growth Accelerators and Market Barriers
Table 37. North America Opioid Narcotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Opioid Narcotics Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Opioid Narcotics Growth Accelerators and Market Barriers
Table 40. Europe Opioid Narcotics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Opioid Narcotics Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Opioid Narcotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Opioid Narcotics Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Opioid Narcotics Growth Accelerators and Market Barriers
Table 45. Southeast Asia Opioid Narcotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Opioid Narcotics Investment Opportunities and Key Challenges
Table 47. Central and South America Opioid Narcotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Opioid Narcotics Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Opioid Narcotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Yichang Renfu Pharmaceutical Co., Ltd. Corporation Information
Table 51. Yichang Renfu Pharmaceutical Co., Ltd. Description and Major Businesses
Table 52. Yichang Renfu Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 53. Yichang Renfu Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Yichang Renfu Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 55. Yichang Renfu Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 56. Yichang Renfu Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 57. Yichang Renfu Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 58. Yichang Renfu Pharmaceutical Co., Ltd. Recent Developments
Table 59. Jiangsu Enhua Pharmaceutical Co., Ltd. Corporation Information
Table 60. Jiangsu Enhua Pharmaceutical Co., Ltd. Description and Major Businesses
Table 61. Jiangsu Enhua Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 62. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 64. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 65. Jiangsu Enhua Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 66. Jiangsu Enhua Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 67. Jiangsu Enhua Pharmaceutical Co., Ltd. Recent Developments
Table 68. Henan Lingrui Pharmaceutical Co., Ltd. Corporation Information
Table 69. Henan Lingrui Pharmaceutical Co., Ltd. Description and Major Businesses
Table 70. Henan Lingrui Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 71. Henan Lingrui Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Henan Lingrui Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 73. Henan Lingrui Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 74. Henan Lingrui Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 75. Henan Lingrui Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 76. Henan Lingrui Pharmaceutical Co., Ltd. Recent Developments
Table 77. Sinopharm Group Industrial Co., Ltd. Langfang Branch Corporation Information
Table 78. Sinopharm Group Industrial Co., Ltd. Langfang Branch Description and Major Businesses
Table 79. Sinopharm Group Industrial Co., Ltd. Langfang Branch Product Models, Descriptions and Specifications
Table 80. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales Value Proportion by Product in 2024
Table 82. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales Value Proportion by Application in 2024
Table 83. Sinopharm Group Industrial Co., Ltd. Langfang Branch Sales Value Proportion by Geographic Area in 2024
Table 84. Sinopharm Group Industrial Co., Ltd. Langfang Branch Opioid Narcotics SWOT Analysis
Table 85. Sinopharm Group Industrial Co., Ltd. Langfang Branch Recent Developments
Table 86. Changzhou Siyao Pharmaceutical Co., Ltd. Corporation Information
Table 87. Changzhou Siyao Pharmaceutical Co., Ltd. Description and Major Businesses
Table 88. Changzhou Siyao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 89. Changzhou Siyao Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Changzhou Siyao Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
Table 91. Changzhou Siyao Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
Table 92. Changzhou Siyao Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
Table 93. Changzhou Siyao Pharmaceutical Co., Ltd. Opioid Narcotics SWOT Analysis
Table 94. Changzhou Siyao Pharmaceutical Co., Ltd. Recent Developments
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Major Businesses
Table 97. Pfizer Product Models, Descriptions and Specifications
Table 98. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Pfizer Recent Developments
Table 100. Fresenius Kabi Corporation Information
Table 101. Fresenius Kabi Description and Major Businesses
Table 102. Fresenius Kabi Product Models, Descriptions and Specifications
Table 103. Fresenius Kabi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Fresenius Kabi Recent Developments
Table 105. Daiichi Sankyo Corporation Information
Table 106. Daiichi Sankyo Description and Major Businesses
Table 107. Daiichi Sankyo Product Models, Descriptions and Specifications
Table 108. Daiichi Sankyo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Daiichi Sankyo Recent Developments
Table 110. Abbott Corporation Information
Table 111. Abbott Description and Major Businesses
Table 112. Abbott Product Models, Descriptions and Specifications
Table 113. Abbott Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Abbott Recent Developments
Table 115. GSK Corporation Information
Table 116. GSK Description and Major Businesses
Table 117. GSK Product Models, Descriptions and Specifications
Table 118. GSK Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. GSK Recent Developments
Table 120. Reig Jofre Corporation Information
Table 121. Reig Jofre Description and Major Businesses
Table 122. Reig Jofre Product Models, Descriptions and Specifications
Table 123. Reig Jofre Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Reig Jofre Recent Developments
Table 125. AcelRx Pharmaceuticals, Inc Corporation Information
Table 126. AcelRx Pharmaceuticals, Inc Description and Major Businesses
Table 127. AcelRx Pharmaceuticals, Inc Product Models, Descriptions and Specifications
Table 128. AcelRx Pharmaceuticals, Inc Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. AcelRx Pharmaceuticals, Inc Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid Narcotics Product Picture
Figure 2. Global Opioid Narcotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Fentanyl Product Picture
Figure 4. Remifentanil Product Picture
Figure 5. Sufentanil Product Picture
Figure 6. Global Opioid Narcotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. Opioid Narcotics Report Years Considered
Figure 11. Global Opioid Narcotics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 13. Global Opioid Narcotics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Opioid Narcotics Revenue Market Share by Region (2020-2031)
Figure 15. Global Opioid Narcotics Sales (2020-2031) & (K Units)
Figure 16. Global Opioid Narcotics Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Opioid Narcotics Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Opioid Narcotics Sales Volume Market Share in 2024
Figure 19. Global Opioid Narcotics Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Fentanyl Revenue Market Share by Manufacturer in 2024
Figure 22. Remifentanil Revenue Market Share by Manufacturer in 2024
Figure 23. Sufentanil Revenue Market Share by Manufacturer in 2024
Figure 24. Global Opioid Narcotics Sales Market Share by Type (2020-2031)
Figure 25. Global Opioid Narcotics Revenue Market Share by Type (2020-2031)
Figure 26. Global Opioid Narcotics Sales Market Share by Application (2020-2031)
Figure 27. Global Opioid Narcotics Revenue Market Share by Application (2020-2031)
Figure 28. North America Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 29. North America Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 31. North America Opioid Narcotics Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Opioid Narcotics Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 41. Europe Opioid Narcotics Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Opioid Narcotics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 46. France Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Opioid Narcotics Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Opioid Narcotics Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 61. India Opioid Narcotics Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Opioid Narcotics Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Opioid Narcotics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Opioid Narcotics Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Opioid Narcotics Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Opioid Narcotics Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Opioid Narcotics Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Opioid Narcotics Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Opioid Narcotics Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Opioid Narcotics Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Opioid Narcotics Revenue (2020-2025) & (US$ Million)
Figure 82. Opioid Narcotics Industry Chain Mapping
Figure 83. Regional Opioid Narcotics Manufacturing Base Distribution (%)
Figure 84. Global Opioid Narcotics Production Market Share by Region (2020-2031)
Figure 85. Opioid Narcotics Production Process
Figure 86. Regional Opioid Narcotics Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232